APA (7th ed.) Citation

Cosgrove, C., Backes, F., Scalise, C., Dwivedi, B., Chambers, L., Nagel, C., . . . O'Malley, D. (2025). 1132P Utility of circulating tumor DNA (ctDNA) dynamics for evaluating early treatment response in patients with recurrent/metastatic endometrial (rEC) and recurrent/platinum-resistant ovarian cancer (rPROC). Annals of Oncology, 36, S752. https://doi.org/10.1016/j.annonc.2025.08.1768

Chicago Style (17th ed.) Citation

Cosgrove, C., et al. "1132P Utility of Circulating Tumor DNA (ctDNA) Dynamics for Evaluating Early Treatment Response in Patients with Recurrent/metastatic Endometrial (rEC) and Recurrent/platinum-resistant Ovarian Cancer (rPROC)." Annals of Oncology 36 (2025): S752. https://doi.org/10.1016/j.annonc.2025.08.1768.

MLA (9th ed.) Citation

Cosgrove, C., et al. "1132P Utility of Circulating Tumor DNA (ctDNA) Dynamics for Evaluating Early Treatment Response in Patients with Recurrent/metastatic Endometrial (rEC) and Recurrent/platinum-resistant Ovarian Cancer (rPROC)." Annals of Oncology, vol. 36, 2025, p. S752, https://doi.org/10.1016/j.annonc.2025.08.1768.